Patent rights are recognized as a property asset with an attendant right to exclude. However, recent policy developments highlight that the right to exclude is not inviolable. This paper explores two rapidly evolving exceptions to patent exclusivity, both of which take the form of compulsory licenses. First, under the international Agreement on Trade-Related Aspects of Intellectual Property Rights ("TRIPS"), national governments can compel patent owners to out-license technology in service of greater good. These egalitarian compulsory licenses improve access to technology but undermine patent value. Second, compulsory licenses are increasingly relied upon as an equitable remedy in U.S. patent litigation. Typically referred to as "ongoing royalties," these court-mandated compulsory licenses are a modern alternative to injunctions against adjudged infringers. TRIPS compulsory licenses and ongoing royalties arise under independent legal frameworks, but necessarily invoke parallel economic considerations. While the wisdom of each has been discussed at length by others, this paper explores principles of royalty determination employed in each context. Considering both frameworks, an analysis of where each succeeds and fails is provided, together with an exploration of optimized royalty frameworks.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0098858820919553 | DOI Listing |
Soc Sci Med
December 2024
IZA, Germany; Department of Finance, University of Surrey, UK. Electronic address:
This paper analyzes the effects of private practice on public health provision in Indonesia among doctor heads of primary public health clinics known as puskesmas. We exploit the exogenous variation in the initiation of private practice after the 1997 Ministry of Health regulation 916 that mandated health professionals to apply for a license for private practice after at least three years of compulsory public service after graduation. Instrumental variable estimates, built around this threshold experience of 3 years after 1997 regulation, suggest that dual practitioners (relative to those only engaged in puskesmas) work significantly fewer hours per week at their public posts at the puskesmas but see significantly more public patients.
View Article and Find Full Text PDFMov Disord Clin Pract
November 2024
Department of Neurology; Center of Expertise for Parkinson & Movement Disorders, Radboud university medical center; Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands.
Background: Persons with Parkinson's disease (PD) experience progressive motor and non-motor symptoms which may influence their ability to drive a car. This is experienced as a massive challenge by many affected individuals, for whom being able to drive a car is vital to maintain functional independence.
Objectives: We assessed how the diagnosis of PD affected the possession of a driving license, how people with PD had adapted their driving style, and to what extent they had communicated about their driving ability with their healthcare professionals.
JAMA Oncol
November 2024
Dana-Farber Cancer Institute, Boston, Massachusetts.
Importance: Limited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops, there is an urgent need to reduce prices and improve access to cancer medicines in LMICs to advance pharmacoequity globally.
Observations: Prior strategies to expand access to cancer medicines in LMICs have primarily relied on charity or differential pricing and have yielded limited results.
JAMA Health Forum
November 2024
Arizona State University Consortium for Science Policy and Outcomes, Washington, DC.
Importance: In December 2023, the Biden-Harris Administration released a proposed framework for exercising government march-in rights (effectively granting compulsory licenses for those patents to generic drug makers) under the Bayh-Dole Act on patents on taxpayer-funded drugs, which has renewed questions about whether march-in rights could promote cost savings through generic competition or harm pharmaceutical innovation.
Objectives: To determine the feasibility of using march-in rights to remove patent barriers to generic competition.
Design, Setting, And Participants: This cross-sectional study examined government funding information from multiple sources for patents listed in the Food and Drug Administration (FDA) Orange Book from 1985 to 2023.
Cureus
August 2024
Institute of Forensic Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HUN.
In Hungary, possessing certain weapons (e.g. firearms, bows, air pistols, and air guns mainly over 7.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!